{
    "name": "loteprednol ophthalmic",
    "comment": "Rx",
    "other_names": [
        "Alrex",
        "Lotemax",
        "Inveltys",
        "Lotemax SM",
        "Eysuvis"
    ],
    "classes": [
        "Corticosteroids",
        "Ophthalmic"
    ],
    "source": "https://reference.medscape.com/drug/alrex-lotemax-loteprednol-ophthalmic-343625",
    "pregnancy": {
        "common": [],
        "specific": [
            {
                "type": "Inveltys",
                "description": [
                    "Drug is not absorbed systemically following topical ophthalmic administration and maternal use is not expected to result in fetal exposure to drug"
                ]
            },
            {
                "type": "Lotemax and Alrex",
                "description": [
                    "There are no adequate and well controlled studies in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus",
                    "  ",
                    "Drug shown to be embryotoxic (delayed ossification) and teratogenic (increased incidence of meningocele, abnormal left common carotid artery, and limb flexures) when administered orally to rabbits during organogenesis at a dose of 3 mg/kg/day (35 times the maximum daily clinical dose), a dose which caused no maternal toxicity; no-observed-effect-level (NOEL) for these effects was 0.5 mg/kg/day (6 times the maximum daily clinical dose)",
                    "Oral treatment of rats during organogenesis resulted in teratogenicity (absent innominate artery at ≥5 mg/kg/day doses, and cleft palate and umbilical hernia at ≥50 mg/kg/day) and embryotoxicity (increased post-implantation losses at 100 mg/kg/day and decreased fetal body weight and skeletal ossification with ≥50 mg/kg/day)",
                    "Treatment of rats with 0.5 mg/kg/day (6 times the maximum clinical dose) during organogenesis did not result in any reproductive toxicity; loteprednol etabonate was maternally toxic (significantly reduced body weight gain during treatment) when administered to pregnant rats during organogenesis at doses of ≥5 mg/kg/day",
                    "Oral exposure of female rats to 50 mg/kg/day of loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally toxic treatment regimen (significantly decreased body weight gain), gave rise to decreased growth and survival, and retarded development in the offspring during lactation; NOEL for these effects was 5 mg/kg/day; no effect on the duration of gestation or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the fetal period"
                ]
            },
            {
                "type": "Inveltys",
                "description": [
                    "Drug is not absorbed systemically following topical ophthalmic administration and maternal use is not expected to result in fetal exposure to drug"
                ]
            },
            {
                "type": "Lotemax and Alrex",
                "description": [
                    "There are no adequate and well controlled studies in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus",
                    "  ",
                    "Drug shown to be embryotoxic (delayed ossification) and teratogenic (increased incidence of meningocele, abnormal left common carotid artery, and limb flexures) when administered orally to rabbits during organogenesis at a dose of 3 mg/kg/day (35 times the maximum daily clinical dose), a dose which caused no maternal toxicity; no-observed-effect-level (NOEL) for these effects was 0.5 mg/kg/day (6 times the maximum daily clinical dose)",
                    "Oral treatment of rats during organogenesis resulted in teratogenicity (absent innominate artery at ≥5 mg/kg/day doses, and cleft palate and umbilical hernia at ≥50 mg/kg/day) and embryotoxicity (increased post-implantation losses at 100 mg/kg/day and decreased fetal body weight and skeletal ossification with ≥50 mg/kg/day)",
                    "Treatment of rats with 0.5 mg/kg/day (6 times the maximum clinical dose) during organogenesis did not result in any reproductive toxicity; loteprednol etabonate was maternally toxic (significantly reduced body weight gain during treatment) when administered to pregnant rats during organogenesis at doses of ≥5 mg/kg/day",
                    "Oral exposure of female rats to 50 mg/kg/day of loteprednol etabonate from the start of the fetal period through the end of lactation, a maternally toxic treatment regimen (significantly decreased body weight gain), gave rise to decreased growth and survival, and retarded development in the offspring during lactation; NOEL for these effects was 5 mg/kg/day; no effect on the duration of gestation or parturition when administered orally to pregnant rats at doses up to 50 mg/kg/day during the fetal period"
                ]
            }
        ]
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to any component of the formulation",
                "Most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision; use with caution in the presence of glaucoma; if product is used for ≥10 days, monitor intraocular pressure (IOP)",
                "Use of corticosteroids may result in posterior subcapsular cataract formation",
                "Steroid use after cataract surgery may delay healing and increase the incidence of bleb formation; diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids; examine patient prior to initiating or renewing treatment",
                "Prolonged use of corticosteroids may suppress the host response and thus increase the risk of secondary ocular infections; steroids may mask infection or enhance existing infection",
                "Exercise caution with steroid use in patients with a history of herpes; use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (eg, herpes simplex)",
                "Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application; consider fungus invasion in any persistent corneal ulceration where a steroid has been used or is in use; take fungal cultures when appropriate",
                "Do not allow dropper tip to touch any surface, as this may contaminate the suspension",
                "Do not wear contact lenses during therapy"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Anterior chamber inflammation",
            "percent": "25"
        },
        {
            "name": "Abnormal vision",
            "percent": "5"
        },
        {
            "name": "blurring",
            "percent": "2"
        },
        {
            "name": "Burning on instillation",
            "percent": "2"
        },
        {
            "name": "Chemosis",
            "percent": "4-5"
        },
        {
            "name": "Discharge",
            "percent": "4-5"
        },
        {
            "name": "Dry eyes",
            "percent": "4-5"
        },
        {
            "name": "Epiphora",
            "percent": "1.5"
        },
        {
            "name": "Foreign body sensation",
            "percent": null
        },
        {
            "name": "Itching",
            "percent": null
        },
        {
            "name": "Photophobia",
            "percent": null
        },
        {
            "name": "Anterior chamber inflammation",
            "percent": null
        },
        {
            "name": "Eye pain",
            "percent": null
        },
        {
            "name": "Foreign body sensation",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "Corneal abnormalities",
            "percent": null
        },
        {
            "name": "Eyelid erythema",
            "percent": null
        },
        {
            "name": "Keratoconjunctivitis",
            "percent": null
        },
        {
            "name": "Ocular irritation",
            "percent": null
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "discomfort",
            "percent": null
        },
        {
            "name": "Papillae",
            "percent": null
        },
        {
            "name": "Uveitis",
            "percent": null
        },
        {
            "name": "Conjunctival hyperemia",
            "percent": null
        },
        {
            "name": "Corneal edema",
            "percent": null
        },
        {
            "name": "Eye pain",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Infrequent optic nerve damage",
            "percent": null
        },
        {
            "name": "Visual acuity and field defects",
            "percent": null
        },
        {
            "name": "Posterior subcapsular cataract formation",
            "percent": null
        },
        {
            "name": "Delayed wound healing",
            "percent": null
        },
        {
            "name": "Secondary ocular infection from pathogens",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "herpes simplex",
            "percent": null
        },
        {
            "name": "Perforation of the globe where there is thinning of the cornea or sclera",
            "percent": null
        }
    ]
}